View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 19, 2020

Covid-19 vaccines may only need to reach lowest efficacy bar for approval

By Victoria Smith

Registrational trials for Covid-19 vaccines will have a number of operational obstructions, even upon agreement that they may only need to reach the lowest success bar of 50% protection over at least six months to be deemed a success.

At the beginning of the month, Moderna made several announcements, including that it was completing the design of its Phase III, expected in summer, and that its share price that day peaked at 14%. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena